Figure 1



Figure 2



Figure 3


100
50
0
% inhibition
-9
-8
-7
-6
-5
Log (conc) M
BAK209B11 scFv
Irrelevant scFv

Figure 4A



Figure 4B



Figure 4C



Figure 5


Mean IC50 (pM) against 25 ng/ml human IL-13 in TF-1 proliferation assay
1500
1000
500
0
JES10-5A2
B-B13
BAK502G9
BAK1111D10
BAK1166G02
BAK1167F02
BAK1167F04
BAK1183H4
BAK1184C8
BAK1185E1
BAK1185F8
*p≤0.05
**p≤0.01

Figure 6A



Figure 6B



Figure 6C



Figure 7



Figure 8



Figure 9


100
50
0
% inhibition
-12.5
-10.0
-7.5
Log (conc) M
BAK502G9 IgG4
BAK1167F2 IgG4
BAK1183H4 IgG4
Irrelevant IgG4

Figure 10A



Figure 10B



Figure 11



Figure 12



Figure 13



Figure 14



Figure 15



Figure 16



Figure 17



Figure 18



Figure 19

```
                          10                  20                  30                  40
Human IL-13               MALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNIT
Cynomolgus IL-13          MALLLTTVIALTCLGGFASPSPVPPSTALKELIEELVNIT
                          MALLLTTVIALTCLGGFASP PVPPSTAL ELIEELVNIT

                                50                  60                  70                  80
Human IL-13               QNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIE
Cynomolgus IL-13          QNQKAPLCNGSMVWSINLTAGVYCAALESLINVSGCSAIE
                          QNQKAPLCNGSMVWSINLTAG YCAALESLINVSGCSAIE

                                      90                  100                 110                 120
Human IL-13               KTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLL
Cynomolgus IL-13          KTQRMLNGFCPHKVSAGQFSSLRVRDTKIEVAQFVKDLLV
                          KTQRML GFCPHKVSAGQFSSL VRDTKIEVAQFVKDLL

                                      130
Human IL-13               HLKKLFREGRFN
Cynomolgus IL-13          HLKKLFREGQFN
                          HLKKLFREG FN
```

Figure 20



Figure 20B


Male IgE
Female IgE
% Baseline Serum IgE
250
200
150
100
50
0
0
100
200
300
400
500
600
700
Time post-infusion (h)

Figure 21



** p<0.01 vs s/c control; One-way ANOVA followed by Dunnett's multiple comparisons test

Figure 22



A and B; *p<0.05, ** p<0.01 vs huIL-13 control; One-way ANOVA on log-transformed data, followed by Dunnett's multiple comparisons test.

Figure 23


15
10
5
0
PC_{200} (MCh mg/ml)
*
**
PBS
hIL-13
BAK502G9 1mg/kg
Control mAb 1mg/kg

Figure 24


125
100
75
50
25
0
-25
% maximal response
-12
-11
-10
-9
-8
-7
-6
Log (conc) M
BAK502G9 IgG4
Irrelevant IgG4


a)
100
75
50
25
0
-25
-50
% Difference vs Untreated
**
ns
Untreated
IL-13
Irrel. IgG4+IL-13
Irrel. IgG4
Pre-treatment
b)
100
75
50
25
0
-25
-50
% Difference vs Untreated
*
*
Untreated
IL-13
BAK502G9+IL-13
BAK502G9
Pre-treatment

Figure 25


A.
D-R AUC
Change in AUC (R
0.025
0.020
0.015
0.010
0.005
0.000
-0.005
-0.010
-0.015
-0.020
-0.025
*
Phase I
Phase II
Endpoint
B.
PC30
Change in PC30 (µg/ml)
0.5
0.0
-0.5
-1.0
-1.5
-2.0
Phase I
Phase II
Endpoint
C.
Asc AUC
Change in AUC (R
0.2
0.1
0.0
-0.1
-0.2
**
Phase I
Phase II
Endpoint
D.
Phase I
Phase II
Endpoint
Number of cells (x10³/µL)
25
20
15
10
5
0
-5
-10
*
*
Totals
Macs
Eos
Neuts
Lymph
Mast

Figure 26



Figure 27



Figure 28

Figure 29A





Figure 29B


10
20
30
human IL13P MALLLTTVIALTCLGGFASPGPVPPSTSSLP
murine IL13P MALWVTAVLALACLGGLAAPGPVPRSVSSLP
MAL.T.V.AL.CLGG A.PGPVP S
40
50
60
human IL13P -ALRELIEELVNITQNQKAPLCNGSMVWSIN
murine IL13P LTLKELIEELSNITQDQTPLCNGSMVWSVN
.L.ELIEEL NITQ Q .PLCNGSMVWS.
70
80
90
human IL13P NLTAGMYCAALESLINVSGCSAIEKTQRML
murine IL13P DLAAGGFCVALDSLTNISNCNAIYRTQRIL
L.AG .C AL.SL N.S.C AI .TQR.L
100
110
120
human IL13P SGFCPHKVSAGQFSSLHVRDTKIEVAQFVK
murine IL13P HGLCNRKAPT-TVSSLP--DTKIEVAHFIT
G C .K . SSL DTKIEVA.F.
130
140
150
human IL13P DLLLHLKKLFREGRFN
murine IL13P KLLSYTKQLFRHGPF
LL K.LFR G F

Figure 30



Figure 31

Figure 32